Advice
In the absence of a submission from the holder of the marketing authorisation:
nivolumab (Opdivo®) is not recommended for use within NHSScotland.
Indication under review: in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice232KB (PDF)
Medicine details
- Medicine name:
- nivolumab (Opdivo)
- SMC ID:
- SMC2726
- Indication:
In combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 October 2024